RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:2932

Chronic inflammatory demyelinating polyneuropathy

medium confidenceDisorder

Also known as: CIDP · Chronic inflammatory demyelinating polyradiculoneuropathy

Publications

7,671

94.4th percentile

Trials

79

Interventional, condition-specific

Researchers

1,165

Distinct authors in sample

Gene link

—

Readiness

4/6

Stages with a signal

Clinical definition (Orphanet)

A rare chronic monophasic or relapsing symmetric sensorimotor disorder characterized by muscular weakness with impaired sensation, absent or diminished tendon reflexes, electrodiagnostic features suggestive of demyelination and occasional elevated cerebrospinal fluid (CSF) protein level.

How rare: 1-9 / 100 000 — about one to nine people per hundred thousand.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (3)

chronic inflammatory demyelinating polyneuropathy · chronic inflammatory demyelinating polyradiculoneuropathy · chronic relapsing polyneuropathy

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

4/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    7,671 matched papers (4,645 in last 10 years) Source

  3. Phenotype characterisedPresent

    21 HPO annotations (e.g. Decreased nerve conduction velocity; Areflexia; Unsteady gait) Source

  4. Animal modelNot found

    No Alliance genotype “model of” associations via Monarch for these Mondo IDs

  5. Orphan designationPresent

    2 FDA · 3 EMA designations (1 FDA orphan-indication approval) — e.g. fingolimod Source

  6. Interventional trialPresent

    79 matched on ClinicalTrials.gov (30 recruiting in sample)

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

21

Associated phenotypes · MONDO:0006702

  • Decreased nerve conduction velocity
  • Areflexia
  • Unsteady gait
  • Falls
  • Anti-contactin-associated protein 1 antibody positivity

Showing 5 of 21 — open Monarch for the full list.

Animal models (Monarch / Alliance)

None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

5

Designations · 1 with FDA orphan-indication approval

  • FDA fingolimodChronic inflammatory demyelinating polyneuropathy · 2010-04-30 · Not FDA Approved for Orphan Indication
  • EMA Humanised IgG4 monoclonal antibody against active complement component 1, subcomponent sTreatment of chronic inflammatory demyelinating polyneuropathy · 22/05/2023 · PositiveEMA designation
  • EMA efgartigimod alfaTreatment of chronic inflammatory demyelinating polyneuropathy · 14/01/2022 · PositiveEMA designation
  • FDA Immune Globulin (Human) (Gamunex-C)Chronic inflammatory demyelinating polyneuropathy · 2004-07-27
  • EMA FingolimodTreatment of chronic inflammatory demyelinating polyneuropathy · 02/02/2010 · WithdrawnEMA designation

Sources: FDA OOPD · EMA orphan designations

Open Targets candidates

19

Drugs / clinical candidates · MONDO_0006702

CTD chemicals (MyDisease.info)

4 associated chemicals. Therapeutic evidence is listed first when present — not a treatment recommendation.

  • Pregabalin · therapeutic
  • Methylprednisolone · marker/mechanism
  • Procainamide · marker/mechanism
  • Tacrolimus · marker/mechanism

MyDisease.info · MONDO:0006702

Literature

Is anyone studying this?

7,671

7,671 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

7,671 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

4,645 in the last 10 years · medium confidence · 94.4th percentile (publications denominator)

Phrase hits: 7,671 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,165

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Nobile-Orazio E8 papers · 2026

    Neuromuscular and Neuroimmunology Unit, IRCCS Humanitas Research Hospital, Milan, Italy.

    Papers in Europe PMC
  2. 02
    Rajabally YA8 papers · 2026

    Aston Medical School, Aston University, Birmingham, UK.

    Papers in Europe PMC
  3. 03
    Allen JA6 papers · 2026

    Department of Neurology, University of Minnesota, Minneapolis, Minnesota, USA.

    Papers in Europe PMC
  4. 04
    Karam C6 papers · 2026

    Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

    Papers in Europe PMC
  5. 05
    Querol L6 papers · 2026

    Department of Neurology, Neuromuscular Diseases Unit, Hospital de La Santa Creu I Sant Pau (IR SANT PAU), Universitat Autònoma de Barcelona, Barcelona, Spain.

    Papers in Europe PMC
  6. 06
    Kuwabara S5 papers · 2026

    Department of Neurology, Chiba University Hospital, Chiba University, Chiba, Japan.

    Papers in Europe PMC
  7. 07
    Lewis RA5 papers · 2026

    Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

    Papers in Europe PMC
  8. 08
    Attarian S4 papers · 2026

    Referral Center for Neuromuscular Diseases and ALS, La Timone Hospital, Marseille, France.

    Papers in Europe PMC
  9. 09
    Cui L4 papers · 2026

    Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.

    Papers in Europe PMC
  10. 10
    Dimachkie MM4 papers · 2026

    Neuromuscular Division, Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas, USA.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

79

interventional trials for this specific condition

79 interventional trials matched this specific condition name; 30 currently recruiting in our sample. 4 trials are registered for demyelinating polyneuropathy, the broader category — shown separately because they may or may not enrol this specific subtype.

Data as of 11 September 2026

79 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 98.2th percentile).

medium confidence · 98.2th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

79 interventional trials matched after quoted-phrase search and title/condition post-filter.

Broader category: demyelinating polyneuropathy

4

Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.

Worth raising with a clinician. How we count trials.

Recruiting under the broader category

Observational and natural-history studies

34 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

Recruiting or not-yet-recruiting

Open the complete matched search on ClinicalTrials.gov

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 38 · after dedupe 38 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 38 · dropped 0 · fetched 2026-07-29

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Uncertain / not reviewed (38)

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for Chronic inflammatory demyelinating polyneuropathy — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Chronic inflammatory demyelinating polyneuropathy" OR "Chronic inflammatory demyelinating polyradiculoneuropathy" OR "chronic relapsing polyneuropathy"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Chronic inflammatory demyelinating polyneuropathy" OR "Chronic inflammatory demyelinating polyradiculoneuropathy" OR "chronic relapsing polyneuropathy"

Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 79 interventional · 34 observational · 3 expanded access. Only interventional studies enter the trial headline.

Parent-category trials query:

"demyelinating polyneuropathy"

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Synonyms dropped by stoplist: CIDP

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • 1 synonym(s) dropped by stoplist (may under-count)
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-26T21:43:10.255Z